Adam Schayowitz sells 13,832 Zymeworks shares at $25.85 each, totaling $357,557
On October 12, 2026, Adam Schayowitz, EVP and Head of R&D at Zymeworks, sold 13,832 shares at $25.85 each, totaling $357,557. The transaction was reported on the SEC's Form 4.
Adam Schayowitz, Executive Vice President (EVP) and Head of Research and Development (R&D) at Zymeworks Inc. (ticker: ZYME), sold 13,832 shares on October 12, 2026, at a price of $25.85 per share, generating a gross value of $357,557 as reported in the SEC's Form 4 filing.
Who is Adam Schayowitz and what is his actual role at Zymeworks Inc.
Adam Schayowitz holds the position of Executive Vice President (EVP) and Head of Research and Development (R&D) at Zymeworks, a publicly traded biopharmaceutical company. In his role as EVP, he is part of the executive team that shapes the company's global strategy, oversees budgets, and participates in major capital allocation decisions. As Head of R&D, he is responsible for steering scientific programs, approving clinical trials, and managing the research teams working on Zymeworks' therapeutic protein platforms. This dual role places Schayowitz at the center of confidential information regarding product pipelines, clinical trial results, and R&D partnerships, all of which directly influence the stock's valuation.
The EVP Head of R&D position grants access to non-public data, including regulatory filing dates, preliminary clinical trial results, and licensing negotiations with other companies. These sensitive details are protected under Securities Exchange Act rules, which require executives to report any stock transactions within two business days. The transparency mandated by the Form 4 aims to prevent the misuse of insider information for personal gain.
Transaction details: 13,832 shares at $25.85 each
The official filing indicates that the sale involved exactly 13,832 Zymeworks shares, each sold at a price of $25.85 in US dollars. The transaction was executed on October 12, 2026, as noted in the SEC's EDGAR database. Multiplying the number of shares by the per-share price yields a gross value of $357,557, representing the total proceeds before taxes or transaction fees. It is crucial to distinguish between the per-share price and the total value, as the former reflects the market price at the time of sale, while the latter summarizes the total cash flow generated.
This transaction appears in the public registry of insider trades, which tracks every stock movement by directors, officers, and employees holding restricted shares or options. The Form 4 also specifies the type of transaction (sale), the nature of the holder (insider), and the company code (ZYME). No additional details, such as a prearranged sale plan or a sale linked to an option program, are provided in the document.
Why insiders sell their shares - possible reasons
Executives may decide to liquidate part of their holdings for various reasons that are not necessarily tied to their expectations about the stock's future price. Portfolio diversification is a common motivation: holding a significant stake in a single security exposes the investor to concentration risk, and selling allows rebalancing assets across different classes (equities, bonds, real estate, etc.).
Tax considerations may also play a role. Depending on the fiscal calendar, an executive might choose to sell before the end of a tax year to realize gains or losses that will be reported on their income tax return. Similarly, liquidity needs for personal projects (real estate purchases, education expenses, etc.) can prompt monetizing a portion of their holdings.
It is also possible that the sale is part of an option exercise program or an authorized share repurchase plan by the board of directors. In this scenario, the executive exercises options at an exercise price below the market price and then immediately sells the shares to realize a profit. Some insiders may use sales as a way to signal reduced confidence in the company's short-term trajectory, but this signal should be interpreted with caution, as personal motivations often outweigh fundamental analysis.
How individual investors can track Form 4 filings
Form 4 filings are freely accessible through the SEC's EDGAR website, which aggregates submissions from all US-listed companies. Individual investors can search for the ZYME ticker and filter results by document type to view insider declarations. Third-party platforms like OpenInsider, WhaleWisdom, or Bloomberg offer user-friendly interfaces displaying recent buys and sells, dollar amounts, and ownership percentages.
It is important to note, however, that Form 4 information does not constitute investment advice. The two-day reporting window means market movements may already have priced in the news. Additionally, the transaction size should be evaluated in the context of the insider's total holdings: selling 13,832 shares represents an unspecified percentage of Schayowitz's portfolio. Investors should combine Form 4 analysis with other information sources, such as quarterly reports, press releases, and analyst evaluations, before making investment decisions.
